PEDIATRICS Vol. 91 No. 4 April 1993, pp. 716-720
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strickland, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strickland, A. L.

Long-term Results of Treatment With Low-Dose Fluoxymesterone in Constitutional Delay of Growth and Puberty and in Genetic Short Stature

A. L. Strickland MD1

1 From the Spartanburg Regional Medical Center, Spartanburg, SC.

This prospective study was designed to assess growth response, side effects, other possible longterm effects, and final adult height in boys treated with the oral androgen, fluoxymesterone. From 1973 to 1984, eighty-two short boys (71 with constitutional delay of growth and puberty [CDGP] and 11 with genetic short stature [GSS]) were treated with daily oral doses of 2.5 mg of fluoxymesterone from 6 to 60 months. Final height assessment was made from 1989 to 1991. A group of 34 untreated boys (26 with CDGP and 8 with GSS) were also followed to assess the accuracy of the Greulich-Pyle and Bayley-Pinneau (GP-BP) and sexual maturity index height prediction methods. During treatment, each patient had a 1.7- to 2.5-fold increase in linear growth velocity. Accelerated velocity (over baseline) continued as long as the bone age was less than 14 years. No adverse androgenic effects (or undue acceleration of puberty) were observed. Final height exceeded pretreatment predictions for CDGP + GSS by 6.1 ± 3.5 (SD) cm (GP-BP) and 5.4 ± 3.2 cm (sexual maturity index). It is concluded that a daily oral dose of 2.5 mg of fluoxymesterone can be used to accelerate linear growth in boys with CDGP and GSS when needed to alleviate emotional problems secondary to slow growth and short stature without fear of compromising final adult height.

Key Words: growth • puberty • height • fluoxymesterone

Submitted on June 24, 1992
Accepted on October 19, 1992




This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
J. A. Kemppainen, E. Langley, C.-i. Wong, K. Bobseine, W. R. Kelce, and E. M. Wilson
Distinguishing Androgen Receptor Agonists and Antagonists: Distinct Mechanisms of Activation by Medroxyprogesterone Acetate and Dihydrotestosterone
Mol. Endocrinol., March 1, 1999; 13(3): 440 - 454.
[Abstract] [Full Text]